Common Contracts
2 similar Royalty Purchase Agreement contracts by Longboard Pharmaceuticals, Inc.
Royalty Purchase AgreementRoyalty Purchase Agreement • February 19th, 2021 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Royalty Purchase Agreement (the “Agreement”), dated as of October 27, 2020, is by and between Arena Pharmaceuticals, Inc. (“Parent”), 356 Royalty Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“356”), and Longboard Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the “Company”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in that certain Transaction Agreement, dated as of December 28, 2016, by and among 356, Eisai Inc. and Eisai Co., Ltd. (the “Transaction Agreement”).
Royalty Purchase AgreementRoyalty Purchase Agreement • December 15th, 2020 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Royalty Purchase Agreement (the “Agreement”), dated as of October 27, 2020, is by and between Arena Pharmaceuticals, Inc. (“Parent”), 356 Royalty Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“356”), and Longboard Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the “Company”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in that certain Transaction Agreement, dated as of December 28, 2016, by and among 356, Eisai Inc. and Eisai Co., Ltd. (the “Transaction Agreement”).
